|
This page displays all 「FI」 in main group A61K47/00. |
HB:Handbook | ||||
|
CC:Concordance | |||||
|
|
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient [2] | HB | CC | 4C076 | |
|
|
.Inorganic compounds [5] | HB | CC | 4C076 | |
|
|
..Non-metals; Compounds thereof [5] | HB | CC | 4C076 | |
|
|
.Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite | HB | CC | 4C076 | |
|
|
..containing oxygen [5] | HB | CC | 4C076 | |
|
|
...Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers [2017.01] | HB | CC | 4C076 | |
|
|
...Carboxylic acids; Salts or anhydrides thereof [2006.01] | HB | CC | 4C076 | |
|
|
...Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters [2017.01] | HB | CC | 4C076 | |
|
|
..containing nitrogen [2006.01] | HB | CC | 4C076 | |
|
|
...Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids [2017.01] | HB | CC | 4C076 | |
|
|
..containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids [2006.01] | HB | CC | 4C076 | |
|
|
..Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones [2006.01] | HB | CC | 4C076 | |
|
|
..containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids [2006.01] | HB | CC | 4C076 | |
|
|
..Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin [2006.01] | HB | CC | 4C076 | |
|
|
..Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid [2006.01] | HB | CC | 4C076 | |
|
|
.Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates [2006.01] | HB | CC | 4C076 | |
|
|
..Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers [2006.01] | HB | CC | 4C076 | |
|
|
..Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) [2017.01] | HB | CC | 4C076 | |
|
|
..Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin [2006.01] | HB | CC | 4C076 | |
|
|
...Cellulose; Derivatives thereof [2006.01] | HB | CC | 4C076 | |
|
|
...Cyclodextrins; Derivatives thereof [2006.01] | HB | CC | 4C076 | |
|
|
..Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids A61K47/18; polyamino acids A61K47/34) [2017.01] | HB | CC | 4C076 | |
|
|
.Oils, fats or waxes according to two or more groups of A61K47/02 to A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14) [2017.01] | HB | CC | 4C076 | |
|
|
.Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts [2006.01] | HB | CC | 4C076 | |
|
|
.the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates [2017.01] | HB | CC | 4C076 | |
|
|
..the non-active ingredient being a modifying agent [2017.01] | HB | CC | 4C076 | |
|
|
...the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient [2017.01] | HB | CC | 4C076 | |
|
|
...the modifying agent being an organic compound [2017.01] | HB | CC | 4C076 | |
|
|
....the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds [2017.01] | HB | CC | 4C076 | |
|
|
...the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule [2017.01] | HB | CC | 4C076 | |
|
|
....obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin [2017.01] | HB | CC | 4C076 | |
|
|
....obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes [2017.01] | HB | CC | 4C076 | |
|
|
.....the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol [2017.01] | HB | CC | 4C076 | |
|
|
....the organic macromolecular compound being a polysaccharide or a derivative thereof [2017.01] | HB | CC | 4C076 | |
|
|
...the modifying agent being a protein, peptide or polyamino acid [2017.01] | HB | CC | 4C076 | |
|
|
....Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) [2017.01] | HB | CC | 4C076 | |
|
|
....Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers [2017.01] | HB | CC | 4C076 | |
|
|
....the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells [2017.01] | HB | CC | 4C076 | |
|
|
...the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment [2017.01] | HB | CC | 4C076 | |
|
|
..the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit [2017.01] | HB | CC | 4C076 | |